We create innovative targeted therapeutics to improve the lives of cancer patients.

Machavert’s Science Approach

We are developing novel small molecule RAL GTPase inhibitors that target KRAS mutant cancers growth and metastasis.


Who we are

Our mission and our goals

Machavert is a pharmaceutical company that develops first-in-class targeted therapeutics to treat cancer. Our approach takes advantage of proprietary RAL GTPase inhibitors to control KRAS mutant cancer growth and metastasis.

Our primary goal is to improve the lives of patients suffering from difficult to treat cancers. Machavert currently focuses on the development of novel RAL GTPase inhibitors for IND enabling studies and early clinical trial entry.

Our drug candidates

We develop RAL GTPase inhibitors for targeting KRAS mutant cancers, including non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic cancer. The RAL GTPase inhibitor technology was exclusively in-licensed from the University of Colorado School of Medicine (CU) and represents a novel way of drugging KRAS mutant cancers.

Creativity, collaboration and innovation.

At Machavert, we believe that the key to our success is a close collaboration in a creative team.

We are a group of passionate innovators with multidisciplinary expertise; focused on the challenge to create new ways to treat cancer.

  • Creativity
  • Collaboration
  • Innovation


We have partnered with leading firms to provide us with additional expertise, guidance and resources.

  • Highlighted Partnerships